Cargando…

Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia

The treatment of older patients with acute myeloid leukemia that is secondary to previous myelodysplastic syndrome, myeloproliferative neoplasm, or prior cytotoxic exposure remains unsatisfactory. We compared 92 and 107 patients treated, respectively, with intensive chemotherapy or azacitidine withi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dumas, Pierre-Yves, Bertoli, Sarah, Bérard, Emilie, Médiavilla, Clémence, Yon, Edwige, Tavitian, Suzanne, Leguay, Thibaut, Huguet, Françoise, Forcade, Edouard, Milpied, Noël, Sarry, Audrey, Sauvezie, Mathieu, Bories, Pierre, Pigneux, Arnaud, Récher, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668025/ https://www.ncbi.nlm.nih.gov/pubmed/29108292 http://dx.doi.org/10.18632/oncotarget.15988

Ejemplares similares

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience
por: Bertoli, Sarah, et al.
Publicado: (2019)

Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response
por: Guenounou, Sarah, et al.
Publicado: (2016)

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
por: Galtier, Jean, et al.
Publicado: (2021)

Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study
por: Bertoli, Sarah, et al.
Publicado: (2020)

CD34(+)CD38(−)CD123(+) Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents
por: Vergez, François, et al.
Publicado: (2020)

Dexamethasone in hyperleukocytic acute myeloid leukemia
por: Bertoli, Sarah, et al.
Publicado: (2018)

Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
por: Dumas, Pierre-Yves, et al.
Publicado: (2020)

Improved outcome for AML patients over the years 2000–2014
por: Bertoli, Sarah, et al.
Publicado: (2017)

Vitamin C and D supplementation in acute myeloid leukemia
por: Mouchel, Pierre Luc, et al.
Publicado: (2023)

Cost comparison of post-remission strategies in younger and older AML patients in France
por: Mounie, Michael, et al.
Publicado: (2023)

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
por: Bertoli, Sarah, et al.
Publicado: (2016)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
por: Bories, Pierre, et al.
Publicado: (2020)

Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis
por: Calmettes, Claire, et al.
Publicado: (2018)

Reduce Mortality and Morbidity in Acute Myeloid Leukemia With Hyperleukocytosis With Early Admission in Intensive Care Unit: A Retrospective Analysis
por: Mottal, Nathan, et al.
Publicado: (2020)

Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients
por: Berger, Eloïse, et al.
Publicado: (2019)

Genomic landscape of hyperleukocytic acute myeloid leukemia
por: Largeaud, Laetitia, et al.
Publicado: (2022)

Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia
por: Vergez, François, et al.
Publicado: (2022)

Impact of Mutational Status and Prognostic Factors on Survival in Chronic Myelomonocytic Leukemia With Systemic Inflammation and Autoimmune Disorders
por: Dussiau, Charles, et al.
Publicado: (2023)

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission
por: Dumas, Pierre‐Yves, et al.
Publicado: (2019)

Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia
por: Vial, Jean Philippe, et al.
Publicado: (2021)

Multiple Severe Toxicities of L-Asparaginase and Their Innovative Management during Induction Therapy of Acute Lymphoblastic Leukemia in an Adult Patient
por: Beziat, Guillaume, et al.
Publicado: (2019)

Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
por: Fernandez, Solène, et al.
Publicado: (2019)

In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
por: Devillier, Raynier, et al.
Publicado: (2022)

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
por: Laloi, Louise, et al.
Publicado: (2022)

Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
por: Récher, Christian, et al.
Publicado: (2021)

A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
por: Bérard, Emilie, et al.
Publicado: (2022)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience
por: LaRochelle, Olivier, et al.
Publicado: (2011)

Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
por: Ramsey, Haley E., et al.
Publicado: (2020)

P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE
por: Döhner, Hartmut, et al.
Publicado: (2023)

Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey
por: Bories, Pierre, et al.
Publicado: (2018)

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
por: Raffoux, Emmanuel, et al.
Publicado: (2010)

Economic Evaluation of Azacitidine in Elderly Patients with Acute Myeloid Leukemia with High Blast Counts
por: Coyle, D., et al.
Publicado: (2019)

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
por: Pollyea, Daniel A., et al.
Publicado: (2022)

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
por: Pollyea, Daniel A., et al.
Publicado: (2022)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
por: Bhatt, Anjali, et al.
Publicado: (2022)

Brachytherapy for uterine cervix-limited acute myeloid leukemia relapse
por: Beziat, Guillaume, et al.
Publicado: (2022)

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies
por: Tavitian, Suzanne, et al.
Publicado: (2015)

Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia
por: Crinier, Adeline, et al.
Publicado: (2020)

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia
por: Vidal, Valérie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rrvpi541gh2paedb0e9nrtf82b